The Lancet Microbe recently published an update on the current #Lassafever outbreak in Nigeria. Here are the facts: ◾ The NCDC has reported 928 confirmed cases and 162 associated deaths as of June 30. ◾ The number of suspected cases has increased compared to the same period last year. Although no vaccine is currently available to manage the outbreak, a Phase 2 clinical trial is underway in Nigeria for IAVI's Lassa fever vaccine candidate. The candidate is built on the same rVSV vaccine vector technology as a licensed Ebola vaccine. Our Head of EIDs, Swati Gupta, emphasizes the promise of this technology – which is used across all IAVI EID vaccines. 📢 “The good thing about this particular technology and platform is that it works very quickly. We know that the immunity develops quite rapidly, and we also know that it only requires one dose..." Read the full article to hear from Gupta and Abdulwasiu Bolaji Tiamiyu, the principal investigator of the trial in Nigeria: https://lnkd.in/en9qp7pZ HJF Medical Research International | CEPI (Coalition for Epidemic Preparedness Innovations)
IAVI
Research Services
New York, NY 34,506 followers
Translating science into global health impact.
About us
Translating scientific discoveries into affordable, globally accessible public health solutions. IAVI is a non-profit that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases.
- Website
-
www.iavi.org
External link for IAVI
- Industry
- Research Services
- Company size
- 201-500 employees
- Headquarters
- New York, NY
- Type
- Nonprofit
- Founded
- 1996
- Specialties
- AIDS vaccine, research and development, product development partnership, HIV/AIDS, vaccine development, global health, capacity strengthening, clinical trials, and scientific research
Locations
-
Primary
125 Broad St
9th Floor
New York, NY 10004, US
Employees at IAVI
Updates
-
We're #hiring a new Medical Director, Clinical Development in Nairobi County. Apply today or share this post with your network.
-
IAVI's Yvonne Wangũi Machira, director of socio-behavioral research, spoke to Devex about the continued need for engagement with communities during the rollout of HIV prevention tools. “But when oral PrEP rolled out in Kenya and many other African countries, the messaging was that it’s targeting certain key populations, targeting gay men, targeting sex workers. And there’s already so much stigma around those populations,” Machira said. “So what happened is that we’ve had a black market in Nairobi evolve around oral PrEP, where people actually buy the oral PrEP instead of accessing it for free in a public health facility because there’s less stigma, less questions asked.” The UPTAKE study (www.uptakestudy.org), led by IAVI and our partners, aims to better understand these gaps. Findings presented at #AIDS2024 revealed that, although 61% of adolescent girls and young women were aware of oral PrEP, only 12% were using it. 🔍 How can researchers and policymakers overcome this hesitancy? Read the article: https://lnkd.in/d_iZKN6f
Spoiled for choice? What's blocking uptake of HIV prevention tools
devex.com
-
IAVI reposted this
⏰10 weeks to go!⏰ With the World Vaccine Congress slowly approaching in 10 weeks, here are 10 speakers you can't miss! 🔹Dr Thomas Waite, Deputy Chief Medical Officer, UK Department of Health and Social Care 🔹Dr Chandresh Harjivan, Special Assistant to the President, Domestic Preparedness and Response to Biological Threats, The White House Office of Pandemic Preparedness and Response Policy, Executive Office of the President 🔹Prof Petro Terblanche, CEO, Afrigen Biologics (Pty) Ltd 🔹Prof Isabel Oliver, Chief Scientific Advisor Transition Lead, UK Health Security Agency 🔹Prof Jeffrey William Almond, FMedSci. Visiting Professor of Microbiology, University of Oxford 🔹Prof Teresa Lambe, Calleva Head Of Vaccine Immunology, University of Oxford 🔹Ab Osterhaus, Director, Research Centre for Emerging Infections & Zoonoses, University of Veterinary Medicine Hannover 🔹Dr Nicolas Collin, Co-Founder & CEO, Vaccine Formulation Institute 🔹Dr Swati Gupta, Vice President, Head of Emerging Infectious Diseases and Scientific Strategy, IAVI 🔹Dr Dan Wolfe, Branch Chief, CBRN Vaccines, Biomedical Advanced Research and Development Authority (BARDA) For speaking opportunities, apply here! https://buff.ly/46VZhqS or get in touch with Anna Louise Hindley-Skelt (anna.hindley-skelt@terrapinn.com)💫 Join us for the largest and most established European meeting on vaccine R&D! Register now, only from €495 https://buff.ly/46ZeNlO 📆Pre-Congress Workshops | 28 October 2024 📍Catalonia Barcelona Plaza 📆Main Congress | 29 – 31 October 2024 📍Fira de Barcelona Montjuic #WVCEU #VaccineDevelopment #VaccineInnovation #HealthcareInnovation #Vaccines
-
-
We're #hiring a new Senior Director, Global Access in Nairobi County. Apply today or share this post with your network.
-
IAVI reposted this
The deadline for early registration for the 7th #GlobForumTBVax ends today! Don't miss these exclusive rates to join the global #TBvaccine community as we come together in Rio de Janeiro from 8-10 October 2024! #7GFTBV 📅 Deadline: 15 August 2024 🎓 Discounted registration for students & participants from low- & middle-income countries 🔗 Register at bit.ly/7GFTBVreg
-
-
Amplifying this announcement from Africa CDC. #Mpox is a zoonotic disease that requires urgent action from the global health community. “We need to have vaccines. Today, we are just talking about almost 200,000 doses [becoming] available. We need at least 10 million doses.” - Dr. Jean Kaseya, director general of Africa CDC More info: https://lnkd.in/eVT7-pZa #VaccinesWork #EIDs
Today, we declare #Mpox a Public Health Emergency of Continental Security. With 2,863 confirmed cases and 517 deaths across 13 African countries in 2024 alone, Mpox is a crisis demanding our collective action. Africa CDC is activating resources, partnerships, and leading coordinated and strategic responses to protect our continent. We call on global partners to join us in this fight. Read More - https://lnkd.in/dcVJevqd #PublicHealthEmergency #ContinentalSecurity #GlobalSolidarity
-
-
We're #hiring a new Associate Director, Global Quality Assurance in Nairobi County. Apply today or share this post with your network.
-
IAVI reposted this
The deadline for early registration for the 7th #GlobForumTBVax ends tomorrow! Don't miss this exciting opportunity to join the global #TBvaccine community as we come together in Rio de Janeiro from 8-10 October 2024! #7GFTBV 📅 Deadline: 15 August 2024 🎓 Discounted registration for students & participants from low- & middle-income countries 🔗 Register at bit.ly/7GFTBVreg
-
-
💡 "Antimicrobial resistance (#AMR) is a growing public health crisis that requires innovative solutions." An article featuring IAVI's AMR expert, Stephen Baker, was published in Nature Communications. It explores combining machine learning algorithms with high-content imaging to better understand AMR – in this case, Salmonella Typhimurium. Read here: https://lnkd.in/eZnm8kKZ
Combining machine learning with high-content imaging to infer ciprofloxacin susceptibility in isolates of Salmonella Typhimurium - Nature Communications
nature.com